&w=3840&q=100)
Dhruva Space to deploy two payloads using its home-built satellite platform
The Hyderabad-based start-up will launch payloads from Australia's Akula Tech and Esper satellites aboard its P-30 satellite platform on a SpaceX Falcon 9 rocket in Q3 of the current fiscal. AI payload Nexus-01 (Akula Tech) and hyperspectral imager OTR-2 (Esper) will fly on Dhruva's P-30 platform, which was successfully tested on ISRO's POEM-3 mission in January 2024.
The LEAP-1 mission is officially slated to launch aboard SpaceX's Falcon 9 in Q3 2025, marking not just a significant Indo-Australian collaboration, but also growing support from the United States in Dhruva Space's global commercial journey, the company said.
"Following a successful qualification of the P-30 onboard ISRO's PSLV-C58, Dhruva Space is excited to take its indigenously developed P-30 satellite platform to the global market," said Sanjay Nekkanti, CEO and co-founder of Dhruva Space.
Dhruva Space's hosted payload offering LEAP (Launching Expeditions for Aspiring Payloads) integrates Ground Station-as-a-Service (GSaaS) and its proprietary Integrated Space Operations and Command Suite (ISOCS) for real-time mission management and payload data downlinking.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
Miners and banks drive Australian shares higher
Aug 5 (Reuters) - Australian shares climbed on Tuesday, driven by gains in miners and banks, while investors globally firmed their bets for a U.S. rate cut in September after last week's soft jobs data. The S&P/ASX 200 index rose 0.9% to 8,741.60 by 0037 GMT, trading near its record high of 8,776.40 hit on July 18. Data released on Friday showed that U.S. employment growth was weaker than expected in July while the nonfarm payrolls count for the previous two months was revised down, raising fears of slowing growth in the world's largest economy. The weaker numbers bolstered expectations for a Federal Reserve interest rate cut in September, with the CME Fedwatch tool showing a more than 94% probability. In Sydney, index heavyweight miners gained 1.4% after iron ore prices strengthened overnight, helped by firm near-term demand in top consumer China. Mining giants Rio Tinto and BHP gained 1.1% and 1%, respectively. Gold stocks jumped 2.2%, with Northern Star Resources rising 3.1%. Banks advanced 0.8%, with the "Big Four" banks gaining between 0.4% and 1.2%. The Reserve Bank of Australia is set to announce its next cash rate decision on August 12, and investors are pricing in a 51% chance of an interest rate cut, according to the RBA Watch tool. In July, the central bank left rates steady at 3.85%. Technology stocks tracked their U.S. peers higher and were last up 1.6%. WiseTech Global climbed 1.4%. Among individual stocks, TPG Telecom fell 2.5% as the company cut its annual pro-forma earnings forecast. Earlier in the day, it rallied as much as 4.2% to its highest since August 2022. In New Zealand, the benchmark S&P/NZX 50 index rose 0.6% to 12,764.82, ahead of the second-quarter jobs report due on Wednesday. The Reserve Bank of New Zealand policy decision is due on August 20 and investors have priced in an 80% chance of a 25-basis-point rate cut. (Reporting by Shivangi Lahiri in Bengaluru; Editing by Subhranshu Sahu)
Mint
an hour ago
- Mint
Global markets today: Nikkei 225, Kospi rises after Trump increases tariffs on Indian exports
Global markets today: Asian markets moved higher after U.S. President Donald Trump revealed intentions to sharply increase tariffs on Indian exports to the U.S. Trump announced on Monday that he plans to significantly increase tariffs on Indian goods in response to India's imports of Russian oil. In turn, New Delhi described the U.S. president's move as 'unjustified' and stated it would take steps to protect its interests. 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits,' Trump wrote on the social media platform Truth Social. Japan's Nikkei 225 advanced by 0.54 per cent, and the Topix edged up 0.45 per cent. South Korea's Kospi climbed 1.77 per cent, while the Kosdaq, focused on small-cap stocks, rose 1.83 per cent. Australia's S&P/ASX 200 also registered a gain of 0.84 per cent. On Monday, all three major U.S. stock indexes posted their biggest single-day percentage gains since May 27, as investors looked for buying opportunities following the previous session's selloff and increased expectations of a September interest rate cut due to weaker-than-anticipated jobs data released on Friday. The Dow Jones Industrial Average rose by 585.06 points, or 1.34 per cent, to close at 44,173.64. The S&P 500 advanced 91.93 points, or 1.47 per cent, to 6,329.94, while the Nasdaq Composite surged 403.45 points, or 1.95 per cent, finishing at 21,053.58. The second-quarter U.S. earnings season is nearing its end, but investors are still anticipating key reports this week from companies such as Walt Disney, opens new tab. Tesla shares climbed 2.2 per cent after the electric car company awarded CEO Elon Musk 96 million shares, valued at approximately $29 billion. (With inputs from agencies) Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
an hour ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
